Kerala ayurveda Limited has announced that its Board of Directors will convene on February 12, 2026, to deliberate on key financial and strategic matters. The meeting has been scheduled in compliance with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Agenda

The board meeting will address three primary items that could significantly impact the company's financial position and capital structure:

Financial Results Review

The board will consider and approve the unaudited financial results for both standalone and consolidated operations covering the quarter and nine months ended December 31, 2025. This review will provide stakeholders with insights into the company's performance during the third quarter of fiscal year 2026.

Preferential Issue Proposal

A significant agenda item involves evaluating a proposal for preferential issue of equity shares. The proposal encompasses the possibility of issuing shares in one or more tranches, adhering to the provisions outlined in SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and the Companies Act, 2013. The implementation of this proposal will be subject to obtaining necessary statutory and regulatory approvals.

The board may also decide to convene an extraordinary general meeting to seek shareholders' approval for the proposed preferential issue, as mandated by regulatory requirements.

Trading Window Restrictions

In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct, Kerala Ayurveda Limited has implemented trading restrictions for designated persons. The trading window has been closed from December 31, 2025, and will remain closed until 48 hours after the announcement of the unaudited financial results for the quarter and nine months ended December 31, 2025.

Corporate Information

Kerala Ayurveda Limited operates as an ISO 9001:2015 certified company with its registered office located in Ernakulam, Kerala, and corporate office in Bengaluru. The company's scrip code on the Bombay Stock Exchange is 530163, and it operates under CIN: L24233KL1992PLC006592.

Kerala Ayurveda has received a settlement order from the Securities and Exchange Board of India (SEBI), marking a significant regulatory development for the company.

Regulatory Settlement

The company has formally received the settlement order from SEBI, India's capital markets regulator. Settlement orders represent a mechanism through which regulatory matters are resolved between companies and SEBI without proceeding through the complete adjudication process.

Settlement Process

SEBI's settlement mechanism allows entities to resolve regulatory issues by agreeing to specific terms and conditions. This process typically involves the payment of settlement amounts and compliance with prescribed conditions, enabling companies to avoid prolonged regulatory proceedings.

Company Status

With the receipt of this settlement order, Kerala Ayurveda has formally concluded its regulatory matter with SEBI. The settlement represents the completion of the regulatory process between the company and the market regulator.